January 2008
Inside Tucson Business;1/21/2008, Vol. 17 Issue 32, p9
The article offers news briefs related to biosciences in Arizona in 2008. ClinXus, a nonprofit organization and a life-sciences alliance, along with the Critical Path Institute (C-Path), created a consortium for the development and testing of drugs to determine their safety. AmpliMed Corp. discovered positive one-year survival results from phase one and two tests of its Amplimexon, a drug for metastastic malignant melanoma.


Related Articles

  • Hope in translation.  // Nature;9/30/2010, Vol. 467 Issue 7315, p499 

    An introduction to the journal is presented in which the editor discusses a research on early-phase clinical drug testing for melanoma by Bollag and colleagues, the translational trend in screening of cancer, and the publisched preclinical papers related to early-phase clinical trials.

  • Pfizer Layoffs Are Opportunity For State.  // Grand Rapids Business Journal;1/29/2007, Vol. 25 Issue 5, p4 

    The article reflects on the significance of the decision of Pfizer to layoff life science workers in Michigan. Southwest Michigan First chief executive officer (CEO) Ronald Kitchens cites that there is a demand among life sciences firms in the region for skilled people in the pre-clinical phase...

  • Trial investigating elesclomol with, without predetermined paclitaxel did not reach endpoint. Adams, Stacey L.; Leiser, Mark; Shafer, Emily; Taliercio, Adam; Volansky, Rob // Hem/Onc Today;4/25/2013, Vol. 14 Issue 8, p44 

    The article reports on the termination of a phase 3 trial to investigate paclitaxel with or without elesclomol on advanced melanoma treatment due to an imbalance of mortality and a failure to achieve a predetermined progression-free survival (PFS).

  • AmpliMed Downsizing After Pancreatic Cancer PII Failure. Young, Donna // BioWorld Today;7/13/2010, Vol. 21 Issue 133, p1 

    The article reports on the decision of AmpliMed Corp. to downsize following the failure of the midstage trial of its pancreatic cancer drug Amplimexon and due to the current economic climate. According to Robert Dorr, chief executive officer (CEO) of Amplimed, the number of employees were...

  • ACRES and CTO sign collaborative agreement. Whalen, J. Michael // CenterWatch Weekly;10/19/2015, Vol. 19 Issue 41, p1 

    The article reports on the collaborative agreement between nonprofit organizations Alliance for Clinical Research and Safety (ACRES) and Clinical Trials Ontario (CTO) to address the global challenges on clinical trials and global therapies.

  • ASCO 2010.  // BioWorld Today;6/9/2010, Vol. 21 Issue 110, p3 

    The article offers information on a review of the design of the Phase III trial of Abraxane from Abraxis BioScience for the treatment of melanoma.

  • (11) GLAXOSMITHKLINE PLC's.  // MondayMorning;9/9/2013, Vol. 21 Issue 32, p11 

    The article reports that drugmaker Glaxosmithkline PLC's second trial of the cancer vaccine MAGE-A3 failed. It states that the vaccine didn't help patients with melanoma but the company has decided to go ahead with the third trial. It mentions that the third trial will be on patients with a...

  • Deals roundup.  // Medical Device Daily;12/6/2007, Vol. 11 Issue 221, p4 

    The article announces that Barberton Citizens Hospital, an acute care facility in Ohio, has been sold to Summa Health System. The not-for-profit health system was a minority joint venture partner in the hospital, previously owning a 3.25 percent interest.

  • (FUNDRAISING) Effort Promotes, Assists Collaborations.  // Children & Youth Funding Report;10/1/2010, p12 

    The article informs about the Catalyst Fund for Nonprofits, which is intended to support a range of ventures, from sharing of back-office functions, to joint purchasing agreements, to partnerships, joint ventures, and, where appropriate, full mergers, among nonprofits to deliver greater impact...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics